Putera, Ikhwanuliman;
van Daele, Paul L. A.;
ten Berge, Josianne C. E. M.;
Dik, Willem A.;
La Distia Nora, Rina;
van Hagen, P. Martin;
Rombach, Saskia M.
Long-term follow-up after treatment of tubercular uveitis: case series and review of the literature
You can manage bookmarks using lists, please log in to your user account for this.
Media type:
E-Article
Title:
Long-term follow-up after treatment of tubercular uveitis: case series and review of the literature
Contributor:
Putera, Ikhwanuliman;
van Daele, Paul L. A.;
ten Berge, Josianne C. E. M.;
Dik, Willem A.;
La Distia Nora, Rina;
van Hagen, P. Martin;
Rombach, Saskia M.
Published:
Frontiers Media SA, 2023
Published in:
Frontiers in Ophthalmology, 3 (2023)
Language:
Not determined
DOI:
10.3389/fopht.2023.1270948
ISSN:
2674-0826
Origination:
Footnote:
Description:
IntroductionThere is a scarcity of long-term follow-up data and management strategies for recurrent uveitis in tubercular uveitis (TBU), especially in cases extending beyond 10 years after the completion of initial antitubercular treatment (ATT).MethodsThis retrospective study involved five TBU patients who were initially treated with a combination of four-drug ATT for 6 months, and the five of them had more than 10 years of follow-up after uveitis resolution upon ATT completion. We describe the occurrence of recurrent uveitis and present our approach to managing these recurrent episodes.ResultsRecurrent uveitis and cystoid macular edema (CME) developed in three out of five included TBU patients with a median of 18 years (range 13–20 years) of follow-up. The anatomical sites of the recurrences were anterior, intermediate, and pan-uveitis. The recurrent episodes varied from 6 years to 15 years after ATT completion. Systemic or local corticosteroids/immunosuppressants successfully resolved all recurrent episodes, but one was also treated with the combination of isoniazid monotherapy again. Two patients needed anti-tumor necrosis factor-α therapy.ConclusionLong-term monitoring of TBU patients after ATT completion is warranted. Further well-designed studies with larger sample sizes are required to better estimate the risk of recurrences, investigate the underlying mechanism of recurrences, and identify biomarkers that predict who is at risk for recurrences.